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Oxidative stress plays an important role in the development of complications in diabetes mellitus. Antioxidant therapy has been
thought to decrease oxidative stress. The objective of the present study was to explore the eﬀects of melatonin (MLT) on oxidative
stress in diabetic rat eye and brain tissue by using immunohistochemical methods. Diabetes was induced by streptozotocin,
(STZ,55mg/kg/i.p) in adult rats. MLT was given 10mg/kg/i.p once a day for 2 weeks beginning from the sixth week. Six weeks
later, rats were divided into three groups: control (CR), STZ-induced diabetic (STZ), and STZ-induced diabetic group received
melatonin (STZ+MLT). Although no signiﬁcant diﬀerence was observed with respect to antioxidant status, NOS activity tended to
behigherintheuntreateddiabeticratsthaninthetreatedrats.ItwasobservedthatMLTtreatmentimprovedthehistopathological
changes including apoptosis and oxidative stress in brain and eye in diabetic rat.
1.Introduction
Diabetesmellitusisachronicdisorderassociatedwithhyper-
glycemia, hyperlipoproteinemia, and oxidative stress [1, 2].
Oxidativestressappearstobethemostimportantpathogenic
factor in underlying diabetic complications [1, 3]. Reac-
tive oxygen species (ROS) can modulate cellular function,
receptor signals, and immune responses in physiological
conditions, but excessive production of ROS can mediate
progressive endothelial damage through growth and migra-
tion of vascular smooth muscle and inﬂammatory cells,
causing alteration of extracellular matrix and apoptosis of
endothelial cells [4, 5]. ROS alter vascular tone by increas-
ing concentration of cytosolic calcium and reducing the
bioavailability of vascular NO relates to its rapid oxidative
inactivation resulting decreased availability of nitric oxide
[6, 7]. Recent investigations indicated that during oxida-
tive stress elevation of ROS and reduction of superoxide
dismutase were accompanied by induction of iNOS and
increased NO-ROS reaction and also increased collagen,
TGF-β1,plasminogenactivatorinhibitor,andapoptosiswere
found in diabetic tissues [7, 8].
Melatonin (N-acetyl-5-methoxytryptamine) is anendog-
enous neurohormone derived from tryptophan, that is,
mainly released from the pineal gland [9–11]. Melatonin
participates in a number of physiological processes like the
reproduction regulation and circadian rhythms, at the same
time is a well-known potent antioxidant and well toleratant
upon its administration [12, 13]. Melatonin is an eﬀective
scavenger of diﬀerent ROS, such as hydroxyl and peroxyl
radicals cross all morphophysiological barriers, is distributed
throughout all cells and also has a powerful capacity to
scavenge free radicals and prevents tissue damage [9, 14]. In
a recent study, melatonin was showed to decrease oxida-
tive stress in streptozotocin-induced diabetic rats [15]. In
another study, S´ aenz et al. indicates that melatonin could2 The Scientiﬁc World Journal
be a potent inhibitor of the retinal nitridergic pathway [16].
Therefore, we designed this study to investigate the eﬀects of
MLT treatment on the eye and brain of the diabetic rat using
immunologicalandhistologicalmethodsrelatedtoapoptosis
and oxidative stress.
2.MaterialsandMethods
Eighteen male Wistar rats (250–350g) had access to labora-
tory food and water ad libitum. They were housed in cages
under standard laboratory conditions (light period between
07:00–19:00h; 21±2◦C; relative humidity 55%). This study
was approved by the Institutional Animal Care Ethics
Committee of Celal Bayar University, Turkey. Diabetes was
induced by a single intraperitoneal injection of streptozo-
tocin(STZ,Sigma,St.Louis,MO;55mg/kg,freshlydissolved
in distilled water). Twenty-four hours after STZ treatment,
development of diabetes in the experimental groups was
conﬁrmed by measuring blood glucose levels in blood
samples taken from the tail vein; rats with blood glucose
levels 250mg/dL were considered diabetic [17]. Six weeks
after STZ treatment, rats were treated with Melatonin (MLT)
i.p at a dose of 10mg/kg/day for two weeks. Similar doses
and durations of melatonin administrations are available in
the literature [15, 18].
Rats that died, got sick, or did not develop diabetes were
excludedfromthestudy. Asaresult,thestudywascompleted
with six rats in each group for a total of 18 rats. Animals
wereassignedrandomlytooneofthreegroupsasfollows:(1)
control group (CT, n = 6), (2) STZ-induced diabetic group
(STZ-DM, n = 6), and (3) ATV-treated STZ-induced dia-
betic group (STZ+MLT, n = 6).
For immunohistochemical staining, sections were incu-
bated at 60◦C overnight and then in xylene for 30min.
After washing with a decreasing series of ethanol, sections
were washed with distilled water and phosphate-buﬀered
saline (PBS) for 10min. Sections were then treated with 2%
trypsin at 37◦C for 15min. After washing with PBS, they
were incubated in a solution of 3% H2O2 for 15min to
inhibit endogenous peroxidase activity. Then sections were
washed with PBS and incubated for 18h at +4◦Cw i t h
primary antibodies: a monoclonal anti-eNOS (rabbit Pab,
RB-1711-P1, Neomarkers, Fremont, CA, USA), anti-iNOS
(rabbit Pab, RB-1605-P, Neomarkers, Fremont, CA, USA),
and antibodies against TGF-β1 (Santa Cruz Biotechnology,
SC146). Afterwards, sections were washed 3 times for 5min
eachwithPBS,followedbyincubation withbiotinylated goat
IgG anti-rabbit IgG and then with streptavidin conjugated
to horse-radish peroxidase for 30min each (Dako LSAB
2 kit, Peroxidase). After washing, 3 times for 5min with
PBS, sections were incubated DAB (Dako) for 5min to
stain immunolabelling and then with Mayer’s hematoxylin.
Sections were covered with mounting medium and were
analyzed light microscopically with a BX 40 microscope
(Olympus, Tokyo, Japan). Control samples were processed
in an identical manner, but primary antibody was omitted.
Two observers blinded to clinical information evaluated the
staining scores independently. Detection of the apoptotic
cell death in situ using as TUNEL method was used for
programme cell death mechanism. Fragmentation of the
DNA in the nucleus is one of the ﬁrst morphological changes
of the apoptotic process and can be detected in histological
sections using a terminal deoxynucleotidyltransferase-biotin
nick end-labeling method (TUNEL) performed with a com-
mercialkit(DeadEndColorimetricTUNELsystem,Promega
G7130) according to the manufacturer’s instructions. Brieﬂy,
after proteinase K treatment for 10min, the sections were
incubatedat370◦CwithTdTfor60min.Asnegativestaining
control for TUNEL, TdT was omitted during the tailing of
reactions.
The data were expressed as mean ± standard deviation
(SD). The data were analysed using repeated measures of
variance. Tukey Kramer multiple comparisons test was used
to test for diﬀerences among means when ANOVA indicated
a signiﬁcant P value (P<0.05).
3. Results
No obvious motor or sensory deﬁcits were observed in
any of the subjects before the experiment. There was a
signiﬁcant increase in fasting blood glucose levels in STZ
(350 ± 25) diabetic rats compared with the CT (90 ±
18) group. There was no statistically signiﬁcant diﬀerence
between STZ and STZ+MLT groups (319 ± 35). In addition,
there were no pathologic ﬁndings observed in the optic
nerve, whereas endothelial damage was stated in the vessels.
In the brain samples, hippocampus, cortex, and cerebellum
have also shown endothelial damage (Figures 1 and 2). There
were no signiﬁcant pathologic diﬀerences in histological
morphometry (Figure 4) which is used in revealing cell
degenerationanddeathandTUNEL(Figure 3)whic hisused
to evaluate apoptosis. TGF-β1 was used to detect damage in
vascular tissues, and iNOS, and eNOS immunoreactivities
were used to determine oxidative stress. eNOS reactivity
was found to be more than iNOS reactivity, however, there
was minimal increase stated in diabetic rats. MLT treatment
causes decrease in all ﬁndings but it was not statistically
signiﬁcant.
4. Discussion
In our study, we observed no signiﬁcant edema or damage
in the retina and brain in diabetic rats. Basal oxidative stress
was determined in the tissue samples, however, it was not at
level to cause damage. Observed minimal damage found to
be related in apoptosis and oxidative stress in vascular tissue.
MLT treatment reduced the damage and suggested to aﬀect
histopathologic changes by reducing oxidative stress.
Oxidative stress has been implicated in the major com-
plications of diabetes mellitus [3]. Decreased antioxidant
capacity and/or increased production of ROS are the two
common mechanisms that lead to increased oxidative stress
indiabetesmellitus,thereforetissuedamageisfacilitatedNot
onlylipidsbutalsoproteins,carbohydrates,andnucleicacids
are aﬀected by alteration of the oxidant and antioxidant
systems [2, 3]. Our results were well matched to the previous
studiesthatshownoxidativestressinstreptozotocin-inducedThe Scientiﬁc World Journal 3
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Figure 1: Histopathologic image of eye (EYE), hippocampus (HIP), cerebrum (CBR), and cerebellum (CBL) after MLT treatment. (H&E
×200).
iNOS eNOS TGF TNL
Figure 2: Immunohistochemical image of eye (EYE), hippocampus (HIP), cerebrum (CBR), and cerebellum (CBL) after MLT treatment.
Because of the similarity of histologic samples, an image was given for each tissue ×200.
iNOS eNOS TGF TNL
Figure 3: Histolopathology of TUNEL images of eye (EYE), hippocampus (HIP), cerebrum (CBR), and cerebellum (CBL) after MLT
treatment. Because of the similarity of histologic samples, an image was given for each tissue ×200.
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Figure 4: Morphometric analyse of the eﬀect of the MLT treatment
on the damage on eye (EYE), hippocampus (HIP), cerebrum
(CBR), and cerebellum (CBL). Data were expressed as % compar-
isons with control values mean ± standard deviation (SD).
diabetic rats [15]. It was suggested that vascular complica-
tions became more important in this media and veriﬁed by
both experimental and clinical studies. Lower endogeneous
antioxidants and elevated lipid peroxidation levels are risk
factors for the development of macro- and microvascular
diabetic complications such as retinopathy, neuropathy,
nephropathy, cataracts, and atherosclerosis [1, 2]. As oxida-
tive stress is the main cause of diabetic complications admin-
istration of antioxidants appears one of the most reasonable
therapeutic approaches. Some studies showed that diabetic
complications may be reduced by antioxidant therapies and
diﬀerent antioxidants, including vitamins C and E, lipoic
acid, and L-Carnitin, in a variety of experimental animal
models of diabetes. They are also able to improve insulin
and glucose levels and reduce micro- and macrovascular
dysfunction [18, 19].4 The Scientiﬁc World Journal
Melatonin, whose antioxidant properties are well doc-
umented, is attracting increased attention in recent years
and is known to reduce oxidative stress [19, 20]. Melatonin
has produced mainly in pineal gland which is considered
to be one of the most potent antioxidant agents which
have negligible toxicity even in the very high doses [9, 19].
Jaworek et al. [21] have shown that melatonin counteracts
the increase in the ROS-induced lipid peroxidation and
preserves, at least in part, the activity of key antioxidizing
enzymes, such as superoxide dismutase, and an important
role in prevention of gastric and pancreatic damage. In
another study, melatonin was found to reduce apoptosis
and necrosis induced by ischemia/reperfusion injury of
the pancreas [22]. Taken together with the results from
the other studies, this study showed that the relationship
between oxidative stress and cell damage supported by
not only biochemical but also histological ﬁndings. Also
in agreement with the other reports, melatonin treatment
does not attenuate diabetic hyperglycaemia, it eﬀectively
ameliorates oxidative stress accompanying diabetes. In view
of our ﬁndings, melatonin seems to be a promising agent
for diabetes therapy. Another interesting ﬁnding according
to our study that the tissue response to oxidative stress
evolves more quickly in the vascular tissue especially in the
endothelial cells and apoptosis is thought to be a natural
end of this situation. Any change in vascular function results
in chronic endoneurial vascular damage, which in turn
results in the neurodegeneration seen in diabetic patients.
Piotrowskifoundtheactivityofcaspase-3(CPP32)increased
in hippocampus in the diabetic rats and the presence of
neuronal damage and death in the hippocampus and dentate
gyrus in the experimental STZ-induced diabetes [23]. The
eﬀects of the antioxidative treatment support the hypothesis
of an important role of oxidative stress and free radicals
in neuronal pathology in diabetes and ischaemia. In our
previous study, histological disorganization of the SN with
increased NOS and TGF-β1 suggests that apoptosis begins
as a result of oxidative stress in the diabetic SN [24]. These
structural alterations during the progression of diabetic neu-
ropathy also have been reported by other investigators [10].
Together with the results, it can be considered that especially
in tissues containing neurons, the eﬀects of oxidative stress
occurs much more quickly and eﬃciently.
In conclusion, the presented results suggest that mela-
tonin administration might be beneﬁcial for reducing dia-
betic complications by preventing oxidative damage due to
NOS increase in the diabetic rat. However, further molecular
investigations are needed to elucidate the exact mechanism
of action and to examine the potential therapeutic eﬀects of
MLT on diabetic tissue damage and apoptosis.
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